دورية أكاديمية

Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma.

التفاصيل البيبلوغرافية
العنوان: Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma.
المؤلفون: Ritter G; Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA., Ritter-Boosfeld E, Adluri R, Calves M, Ren S, Yu RK, Oettgen HF, Old LJ, Livingston PO
المصدر: International journal of cancer [Int J Cancer] 1995 Sep 15; Vol. 62 (6), pp. 668-72.
نوع المنشور: Journal Article; Research Support, U.S. Gov't, P.H.S.
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print Cited Medium: Print ISSN: 0020-7136 (Print) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
مواضيع طبية MeSH: Immunotherapy, Active*, Gangliosides/*immunology , Gangliosides/*pharmacology , Melanoma/*immunology , Melanoma/*therapy, Adjuvants, Immunologic/pharmacology ; Animals ; Antibody Specificity ; Antigens, Neoplasm/immunology ; BCG Vaccine/pharmacology ; Cattle ; Cricetinae ; Drug Hypersensitivity/etiology ; Humans ; Hypersensitivity, Delayed/chemically induced ; Mice ; Vaccines, Combined/pharmacology
مستخلص: Gangliosides expressed in malignant melanoma are potential targets for immunotherapy. Immunization of melanoma patients with vaccines containing purified GM2 ganglioside has resulted in induction of GM2 antibodies, and high titers of GM2 antibodies have correlated with increased survival. Melanoma ganglioside 9-O-acetyl GD3 is another candidate for ganglioside vaccine construction because of its limited expression in normal human tissues. As purification of 9-O-acetyl GD3 from human melanoma (9-O-acetylated on the terminal sialic acid) is not practical for broad application, we investigated the antibody response of melanoma patients to O-acetyl GD3 from several additional sources: hamster melanoma (7-O-acetyl GD3), bovine buttermilk (mixture of 7-O-acetyl GD3, 9-O-acetyl GD3 and 7,9-di-O-acetyl GD3) and chemically modified GD3 from bovine brain (9-O-acetylated on the subterminal sialic acid). Only immunization with the buttermilk-derived O-acetyl GD3 preparation resulted in consistent production of IgM antibodies. However, the induced antibodies reacted with the immunogen and with 7-O-acetyl GD3 derived from hamster melanoma but not with 9-O-acetyl GD3 or human melanoma cells expressing 9-O-acetyl GD3 on their cell surface. In contrast, all O-acetyl GD3 derivatives used for immunization were recognized by murine MAbs that reacted with 9-O-acetyl GD3, and immunization of mice with buttermilk-derived O-acetyl GD3 resulted in the production of antibodies that reacted with human melanoma cells expressing 9-O-acetyl GD3. Apparently, the human and murine immune systems preferentially recognize different epitopes on these molecules.
معلومات مُعتمدة: CA-08748 United States CA NCI NIH HHS; CA-33049 United States CA NCI NIH HHS; NS-11853 United States NS NINDS NIH HHS
المشرفين على المادة: 0 (Adjuvants, Immunologic)
0 (Antigens, Neoplasm)
0 (BCG Vaccine)
0 (Gangliosides)
0 (Vaccines, Combined)
98743-26-1 (9-O-acetyl-GD3 ganglioside)
تواريخ الأحداث: Date Created: 19950915 Date Completed: 19951103 Latest Revision: 20190708
رمز التحديث: 20231215
DOI: 10.1002/ijc.2910620604
PMID: 7558412
قاعدة البيانات: MEDLINE
الوصف
تدمد:0020-7136
DOI:10.1002/ijc.2910620604